Cipla partners with Qilu to license Keytruda biosimilar for U.S.
India’s Cipla said its U.S. unit entered an exclusive partnership with China’s Qilu Pharmaceutical to license a biosimilar version of Merck’s Keytruda for the U.S. market.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.